Do semaglutide pills work for weight loss?

You've heard about the injection, so what's different about a tablet?

Picture the moment you decide to look into semaglutide: you probably land on articles about weekly injections, auto-injector pens, needle-phobia tips. Then someone mentions there's now a pill version and it sounds almost too convenient to be real. It isn't. On 11 June 2026 the MHRA granted marketing authorisation to Wegovy tablets, making the UK the first country in Europe to license an oral GLP-1 medicine for weight management. This is not an off-label workaround or a grey-market compound, it is a fully approved, regulated product from Novo Nordisk.

The mechanism is the same as the injection: semaglutide activates GLP-1 receptors involved in appetite regulation and slows how quickly the stomach empties, so meals feel satisfying with less food. The difference is the route. Oral semaglutide relies on a co-formulation with SNAC (sodium N-[8-(2-hydroxybenzoyl) aminocaprylate]) to get enough of the molecule through the gut wall and into the bloodstream. That absorption step has one important practical consequence, covered in the next section.

For a fuller picture of how the oral and injectable forms compare on a practical level, the oral semaglutide effectiveness overview on our site sets out the key differences side by side. The short answer here: the pill works through the same biology, produces clinically significant weight loss, and is now a legal, licensed option in the UK.

The trial figures, and how to read them honestly

The phase 3 evidence comes from the OASIS 4 trial: 307 adults with obesity or overweight plus at least one weight-related condition, no diabetes, treated for 64 weeks alongside lifestyle changes. The headline from the MHRA's approval announcement is an average weight reduction of approximately 13.6% versus around 2.4% on placebo, regardless of adherence. Among participants who stayed fully on track with treatment throughout, the average reached roughly 16.6%.

Two points worth holding alongside those numbers. First, the 16.6% figure applies only to the fully-adherent subgroup, it is not the plain average, and framing it as such would be misleading. Second, 13.6% is itself a clinically meaningful reduction; at that level, meaningful improvements in blood pressure, cholesterol and joint load typically follow. Weight loss of this scale doesn't come from the tablet alone. The trial participants also followed a reduced-calorie diet and increased their physical activity. The medicine changes appetite; the patient still has to eat and move differently.

The most common side effects reported were gastrointestinal: nausea, vomiting, diarrhoea, constipation. Around 74% of participants on the active tablet reported at least one GI side effect, compared with 42% on placebo. Most were mild to moderate and settled as the body adjusted, particularly in the early weeks of each dose step. For a detailed look at what to expect, the Wegovy tablet information page covers the full side-effect profile.

How the tablet is taken, and why the timing is non-negotiable

This is where oral semaglutide departs most sharply from just swallowing any other tablet. The absorption mechanism depends on an empty stomach and a very small amount of plain water, up to around 120ml. That means taking it first thing in the morning, before coffee, before breakfast, before anything else orally. You then wait at least 30 minutes before eating, drinking or taking other medicines. Swallow it whole.

The dosing schedule starts at 1.5mg and escalates through 4mg and 9mg to the 25mg maintenance dose, with a minimum of one month at each level. If you're already established on the 2.4mg weekly injection, clinical assessment may allow you to move directly to the 25mg tablet, but that decision belongs to your prescriber, not a general article. For the exact schedule, the patient information leaflet is the definitive source, a prescriber will walk you through it during your consultation.

One genuinely useful aspect: no fridge required. Room-temperature storage makes this the easier option when travelling or when the kitchen fridge is already a logistical project. It's a small thing, but it matters to people whose lives don't sit still long enough for a cold chain. More on the practicalities, including how to access the tablet through a regulated UK pharmacy, is on the Wegovy pill UK access page.

Who can be prescribed it (and what that process looks like

Wegovy tablets are licensed for adults with a BMI of 30 or above, or a BMI between 27 and 29.9 alongside at least one weight-related health condition) for example, raised blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance. A BMI that meets those numbers is a starting point, not a guarantee; the prescriber reviews your full health picture, current medicines and any contraindications before approving treatment.

These are prescription-only medicines. The only legal route to them in the UK is a clinical assessment followed by a prescription from a registered prescriber. At present Wegovy tablets are not available on the NHS (a NICE appraisal would be needed first) so private prescription is the current route for most people. If you are weighing up your options, our guide to semaglutide pills for weight loss goes into more depth on eligibility criteria and what the private prescription pathway involves, and our breakdown of whether semaglutide tablets work addresses the clinical evidence in plain terms. If you want to understand whether you might be suitable, our free consultation is the right first step, a GPhC-registered prescriber reviews your answers the same day, and there is no obligation to proceed.